Incomplete Response in Late-Life Depression: Getting to Remission With Buprenorphine

Model scores of the 29,894 trials active now.

Model score 14% for any early termination, 7% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 11% of the time (407 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2018-02-28. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Responsible party: sponsor investigator (raises risk) · Design
• Design: parallel (raises risk) · Design
• Sponsor's past termination rate: no earlier finished trials (lowers risk) · Sponsor's track record
• Minimum age: 50 (lowers risk) · Who can join
• Disease area, cancer: No (lowers risk) · Disease area
• Drug's FAERS reports marked serious: 31.9% (lowers risk) · Drug's FDA history
• Has a data monitoring committee: Yes (raises risk) · Design
• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: subjectdepressivedisorderthe patientrisk
  Phrases that lowered it: painparticipantsdrinksasymptomaticalcohol
• Disease area, psychiatry: Yes (raises risk) · Disease area
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 0 (raises risk) · Sponsor's track record
• Blinding: triple (raises risk) · Design
• Drug's FAERS reports with a death: 4.5% (lowers risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Collaborators: 1 (raises risk) · Design
• Keywords listed: 3 (lowers risk) · Design
• Maximum age: not given (lowers risk) · Who can join

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Incomplete Response in Late-Life Depression: Getting to Remission With Buprenorphine NCT02263248 · started 2014 · scored riskier than 38% of active trials completed
• Buprenorphine Used With Treatment Resistant Depression in Older Adults NCT02181231 · started 2016 · scored riskier than 41% of active trials completed
• Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg or 50 mg Daily of REL-1017 in MDD NCT03051256 · started 2018 · scored riskier than 53% of active trials completed
• Lofexidine Combined With Buprenorphine for Reducing Symptoms of PTSD and OU Relapse in Veterans NCT04360681 · started 2021 · scored riskier than 34% of active trials completed
• Lurasidone Pediatric Bipolar Study NCT02046369 · started 2014 · scored riskier than 20% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.